We're standing by & we can help. It's free and confidential.*
Or Call Us Now: (800) 476-6070*I agree that submitting this form does not create an attorney client relationship and that Weitz & Luxenberg will use the information I am providing to check for conflicts of interest to determine if the firm can assist me.
Get in touch
Telephone: (212) 558-5500
Fax: (212) 344-5461
New York, NY 10003
Paul J. Pennock is the Chief of the Pharmaceutical and Medical Device litigation department at Weitz & Luxenberg and the firm’s lead litigator in that area.
Litigation Leadership Roles: Mr. Pennock is currently trying the first of what could turn out to be thousands of Fosamax femur fracture cases. Weitz & Luxenberg is taking the lead in a national litigation against Merck, the manufacturer of Fosamax, and Pennock is at the helm. Pennock has been invested in pre-trial preparations, and will now turn his attention to jury selection and Weitz & Luxenberg's evidentiary case. With hundreds of hours already devoted to the case, Pennock said plenty of hard work was still to come. "When my six-year-old says, 'I can't wait until this trial is over,' you know trials are a lot of work," Pennock said.
W&L helped negotiate one of the largest mass tort settlements in recent history. More than 300 W&L clients are part of the settlement. Claimants had recalled DePuy ASR hips implanted and removed prior to August 31, 2013.
A Louisiana jury has awarded an extremely large amount to a W&L client who developed bladder cancer after taking Actos. The verdict orders Takeda Pharmaceuticals to pay $6 billion in punitive damages, and Eli Lilly to pay $3 billion.